Hiddo Lambers Heerspink
University Medical Center Groningen · The George Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hiddo Lambers Heerspink as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:26 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06094920 · Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialUniversity Medical Center Groningen · completed · Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus · principal investigator
- Ph3NCT06058585 · The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectThe George Institute · recruiting · Chronic Kidney Diseases · study chair
- N/ANCT04389827 · Global Kidney Patient Trials NetworkThe George Institute · completed · Kidney Diseases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:26 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.Kidney Int · 2013229 citationsRCR 7.3
- Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.J Am Soc Nephrol · 2012141 citationsRCR 4.4
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.J Am Soc Nephrol · 2019107 citationsRCR 4.5
- Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.Am J Kidney Dis · 201193 citationsRCR 2.8
- Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.Nephrol Dial Transplant · 200845 citationsRCR 1.2
- Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.Clin J Am Soc Nephrol · 202233 citationsRCR 3.3
- Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx.JCI Insight · 202333 citationsRCR 4.5
- 12 citationsRCR 0.6